Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Source: View publication →
In patients with heavily pretreated advanced gastric or gastroesophageal junction cancer, third-line or later treatment with the PD-1 inhibitor nivolumab significantly improved overall survival compared to placebo.
Key Findings
Study Design
Study Limitations
Clinical Significance
The ATTRACTION-2 trial was practice-changing, establishing nivolumab as a standard-of-care option for patients with advanced gastric and gastroesophageal junction cancers whose disease has progressed on two or more prior lines of chemotherapy. It provided the definitive phase 3 evidence needed to integrate immune checkpoint inhibitors into the treatment paradigm for advanced gastric cancer.
Historical Context
Historically, patients with advanced gastric or gastroesophageal junction cancer who exhausted first- and second-line systemic therapies had a dismal prognosis with median survival times around 3 to 4 months. Before ATTRACTION-2, no treatments had consistently demonstrated a survival benefit in the third-line setting. This landmark trial was the first phase 3 study to successfully show an overall survival advantage for a PD-1 inhibitor in advanced gastric cancer. Its success led to the initial regulatory approvals for nivolumab in Asia and laid the groundwork for subsequent trials (like CheckMate-649) that successfully moved immunotherapy into the first-line setting.
Guided Discussion
High-yield insights from every perspective
What is the mechanism of action of nivolumab, and why is advanced gastric cancer a rational target for immune checkpoint blockade therapy?
Key Response
Nivolumab is a monoclonal antibody that blocks the PD-1 receptor on T-cells, preventing its interaction with PD-L1 and PD-L2 on tumor cells and thereby restoring T-cell-mediated anti-tumor immunity. Gastric cancers often possess features that make them immunogenic, such as high mutational burdens, microsatellite instability (MSI-H), or Epstein-Barr virus (EBV) positivity, which create neoantigens that can be recognized by a disinhibited immune system.
A patient with metastatic gastric cancer who progressed on fluoropyrimidine, platinum, and taxane-based therapies is started on nivolumab based on the ATTRACTION-2 trial. What specific immune-related adverse events (irAEs) should be monitored, and how does their management fundamentally differ from standard chemotherapy toxicities?
Key Response
Physicians must monitor for irAEs such as pneumonitis, colitis, hepatitis, endocrinopathies, and dermatitis. Unlike standard chemotherapy toxicities which are typically managed with dose delays, reductions, or supportive care like growth factors, severe irAEs require holding the immunotherapy and initiating high-dose systemic corticosteroids with a slow taper to suppress the autoimmune response.
The ATTRACTION-2 trial demonstrated an overall survival benefit with nivolumab regardless of PD-L1 expression, which contrasts with several Western trials where PD-L1 heavily influences checkpoint inhibitor efficacy in gastroesophageal cancers. How do regional differences in gastric cancer biology and the methodology of evaluating PD-L1 explain these discrepancies?
Key Response
Asian gastric cancers have different clinical and molecular profiles, such as higher rates of distal tumors and H. pylori infection, compared to Western cohorts which have more proximal GEJ tumors. Furthermore, ATTRACTION-2 evaluated PD-L1 expression solely on tumor cells using the Tumor Proportion Score (TPS), whereas later studies demonstrated that the Combined Positive Score (CPS), which includes lymphocytes and macrophages, is a far more accurate predictive biomarker for PD-1 inhibitor efficacy in upper GI malignancies.
In the ATTRACTION-2 trial, nivolumab was compared to placebo in the third-line setting. How do you counsel a heavily pretreated patient about the absolute versus relative survival benefits of this therapy, particularly regarding the 'tail of the survival curve' phenomenon?
Key Response
While the trial showed a statistically significant relative reduction in the risk of death, the absolute median overall survival improvement was modest (5.26 months vs 4.14 months). Counseling requires explaining that while average gains are small, immunotherapy is characterized by a 'tail on the curve' where a subset of patients achieves durable, long-term survival (e.g., 12-month OS was 26.2% for nivolumab vs 10.9% for placebo), which must be weighed against potential toxicities in the palliative setting.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The ATTRACTION-2 study was conducted exclusively in Asian countries. From a methodological and epidemiological standpoint, how does this geographical restriction impact the external validity of the trial, and what study design strategies are necessary to establish global applicability?
Key Response
Genetic, environmental, and standard-of-care differences between Asian and Western gastric cancer populations severely threaten the external validity of this study. To establish global generalizability, researchers must employ multi-regional clinical trials (MRCTs) with pre-planned stratification and adequately powered subgroup analyses by geographic region, alongside harmonization of biomarker assays and subsequent-line treatment protocols.
Given that tissue availability in the third-line setting is often limited to archival primary tumor biopsies, how does temporal and spatial tumor heterogeneity threaten the validity of the PD-L1 subgroup analyses presented in the ATTRACTION-2 manuscript?
Key Response
Using archival tissue from initial diagnosis to assess PD-L1 status in the third-line setting ignores the dynamic nature of the tumor immune microenvironment, which frequently evolves after multiple lines of cytotoxic chemotherapy. A rigorous reviewer would flag that the lack of fresh pre-treatment biopsies severely limits the reliability of the PD-L1 subgroup findings, potentially masking the true predictive value of the biomarker at the exact time of study entry.
Based on the ATTRACTION-2 data and subsequent global trials, should nivolumab be universally recommended as a category 1 option for all patients with advanced gastric cancer in the third-line setting, or should guidelines mandate restriction based on PD-L1 CPS and MSI-H status?
Key Response
While ATTRACTION-2 initially supported a broad approval in Asia, global guidelines like NCCN and ESMO have evolved to heavily prioritize biomarkers. Current guidelines strongly prioritize the use of checkpoint inhibitors for patients with MSI-H/dMMR tumors or high PD-L1 CPS expression, reflecting the nuanced integration of ATTRACTION-2 with trials like CheckMate-649 and KEYNOTE-059, emphasizing biomarker-directed stewardship rather than universal unselected application in later lines.
Clinical Landscape
Noteworthy Related Trials
KEYNOTE-061 Trial
Tested
Pembrolizumab
Population
Advanced gastric or GEJ cancer progressing on first-line chemotherapy
Comparator
Paclitaxel
Endpoint
Overall survival in patients with PD-L1 CPS >= 1
TAGS Trial
Tested
Trifluridine/tipiracil (TAS-102)
Population
Heavily pretreated metastatic gastric or GEJ cancer (>= 2 prior regimens)
Comparator
Placebo
Endpoint
Overall survival
CheckMate 649 Trial
Tested
Nivolumab plus chemotherapy
Population
Previously untreated advanced gastric, GEJ, or esophageal adenocarcinoma
Comparator
Chemotherapy alone
Endpoint
OS and PFS in PD-L1 CPS >= 5
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis